← Leaderboards
Corinne Ida Lasmezas
Scripps Florida
$4,614,823
Attributed
$7,199,339
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2012–23$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,199,339 · 8
By mechanism
R01$4,502,867 · 2
R21$1,065,570 · 2
R41$867,221 · 2
R56$666,166 · 1
R03$97,515 · 1
Top collaborators
- Thomas D Bannister5 shared
- Louis Daniel Scampavia3 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsS DiseaseToxic EffectSmall MoleculeHigh Throughput ScreeningBaseSeriesAnalogNeurodegenerative DisordersNerve DegenerationBrainPathway InteractionsLeadCellsProtein MisfoldingCell SurvivalOxidative StressParkinson DiseasePrion DiseasesIn VivoAmyotrophic Lateral SclerosisInjuryMouse Model
Grant awards (17)
Development of a lead candidate for the treatment of Alzheimer's disease$100,250
R41 · FY2023 · AG · contact PI
Development of a lead candidate for the treatment of Alzheimer's disease$390,685
R41 · FY2022 · AG · contact PI
Early development of small molecule neuroprotectants.$733,123
R01 · FY2021 · NS · contact PI
Early development of small molecule neuroprotectants.$767,106
R01 · FY2020 · NS · contact PI
Early development of small molecule neuroprotectants.$777,326
R01 · FY2019 · NS · contact PI
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.$376,286
R41 · FY2019 · NS · contact PI
Early development of small molecule neuroprotectants.$755,830
R01 · FY2018 · NS · contact PI
Early development of small molecule neuroprotectants$666,166
R56 · FY2017 · NS · contact PI
Mode of action of a neuroprotective compound$192,000
R21 · FY2017 · NS · contact PI
High-throughput screening for NAD+-replenishing neuroprotective compounds$493,891
R01 · FY2016 · NS · contact PI
Mode of action of a neuroprotective compound$336,000
R21 · FY2016 · NS · contact PI
High-throughput screening for NAD+-replenishing neuroprotective compounds$490,988
R01 · FY2015 · NS · contact PI
High-throughput screening for NAD+-replenishing neuroprotective compounds$484,603
R01 · FY2014 · NS · contact PI
Genome-wide screening for effectors of toxic prion protein-induced neuronal death$191,070
R21 · FY2013 · NS · contact PI
High Throughput Screening for compounds reducing cell surface prion protein$48,015
R03 · FY2013 · DA · contact PI
Genome-wide screening for effectors of toxic prion protein-induced neuronal death$346,500
R21 · FY2012 · NS · contact PI
High Throughput Screening for compounds reducing cell surface prion protein$49,500
R03 · FY2012 · DA · contact PI